EP0820270A1 - Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents - Google Patents

Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents

Info

Publication number
EP0820270A1
EP0820270A1 EP96910786A EP96910786A EP0820270A1 EP 0820270 A1 EP0820270 A1 EP 0820270A1 EP 96910786 A EP96910786 A EP 96910786A EP 96910786 A EP96910786 A EP 96910786A EP 0820270 A1 EP0820270 A1 EP 0820270A1
Authority
EP
European Patent Office
Prior art keywords
composition
clay
laponite
salt
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP96910786A
Other languages
German (de)
English (en)
Other versions
EP0820270B1 (fr
EP0820270A4 (fr
Inventor
Kenneth Markowitz
Mikhail Y. Gelfer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Block Drug Co Inc
Original Assignee
Block Drug Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Block Drug Co Inc filed Critical Block Drug Co Inc
Publication of EP0820270A1 publication Critical patent/EP0820270A1/fr
Publication of EP0820270A4 publication Critical patent/EP0820270A4/fr
Application granted granted Critical
Publication of EP0820270B1 publication Critical patent/EP0820270B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the invention is directed to new desensitizers for hypersensitive teeth and to methods of making and using such desensitizers.
  • Dentinal hypersensitivity causes pain in the mouth of a patient when a nerve in an affected tooth is exposed to certain external stimuli, including temperature and tactile stimuli.
  • One possible source of dental hypersensitivity is that the dentin of affected teeth is over-exposed to the stimuli due to injury, disease or some other reason.
  • Dentin generally contains channels, called tubules, rhat allow material and energy transport between the exterior of the dentin and the interior of the tooth where the nerve resides. Exposure of these tubules to external stimuli can cause irritation of the nerve in a tooth, leading to discomfort.
  • Dental hypersensitivity is generally treated by either treating the nerve in the tooth to make it less sensitive to stimuli or by blocking or occluding the tubules to prevent or limit exposure of the nerve to external stimuli and limit the stimulus triggered fluid movements in the dentinal tubules.
  • Treatments that directly affect the nerve generally interfere with the electrolyte balance near the nerve to affect the outer membranes of the nerve so that the nerve does not "fire” as frequently or as strongly as an untreated nerve.
  • Useful agents in treating dental hypersensitivity in this manner include potassium nitrate, as set forth in U.S. Patent No. 3,863,006 to Ffodosh. issued January 28, 1975, potassium chloride, as set forth in U.S. Patent No. 4,751,072 to Kirn. issued June 14, 1988, potassium bicarbonate, as set forth in U.S. Patent No. 4,631,185 to Kim. issued December 23, 1986, and strontium chloride, as set forth in U.S. Patent No. 3,122,483 to
  • Occlusion of the tubules provides an alternative method of treatment.
  • Useful reported agents include polymeric agents such as Caibopol, as set forth in U.S. Patent No. 5,270,031 to Lim et al.. issued December 14, 1993, and certain polystyrene beads, as set forth in U.S. Patent No. 5,211,939 to Tureskv et al .. issued May 18, 1993.
  • Apatite can also be an anti-hypereeniativity agent.
  • U.S. Patent No. 4,634,589 to Schfillsr issued January 6, 1987, and U.S. Patent No. 4,710,372, issued December 1, 1987, also to Scheller, disclose dentifrices for hypersensitive teeth containing apatite having an average particle size of less than 10 microns and optionally a local anesthetic. No other soluble mineral salts are permitted to exert any interfering effect in these patents. The apatite reduces the diameter of the dentin channels.
  • Montmorrolinite clay has also been reported as a desensitizing agent in U.S. Patent No. 4,992,258 to Mason, issued February 12, 1991.
  • mo-itmorrolinite clay is not compatible with most known fluoridating agents and thus has limited use.
  • montmorrolinite clay loses its ability to thicken a dentifrice and has reduced ability to block tubules in the presence of inorganic salts, such as potassium salts, so its use as a desensitizer is limited.
  • U.S. Patent No. 4,081,526 to Asakawa et al issued March 28, 1978 discloses dentifrice compositions comprising 0.5 to 13% of a hectorite clay such as Laponite, for removing plaque from the teeth.
  • the principal object of the present invention therefore is to provide an effective tubule blocking agent that is compatible with fluorides and other conventional dentifrice ingredients and that is also organolepticaily acceptable.
  • the invention provides a desensitizing agent for hypersensitive teeth comprising a hectorite clay, such as Laponite clay.
  • the invention further provides a method for treating hypersensitive teeth by contacting the teeth with a desensitizing formulation comprising a therapeutic amount of a hectorite clay,
  • the invention comprises a composition for treating hypersensitive teeth, such as a dentifrice (eithf-r z p ** __t2 cr a gel) or other appropriate oral vehicle.
  • the composition comprises a hectorite clay in an amount and in a formulation sufficient to desensitize teeth.
  • Preferred hectorite clays include Laponite clays, and especially preferred are treated, so-called “synthetic" hectorite clays such as LAPONTTE D* and LAPONITE DF*, both sold by Southern Clay Products, Inc.
  • LAPONITE DF* has been treated by the addition of fluorine to the clay to prevent absorption of fluoride from dentifrice formulations.
  • Additional preferred Laponite clays, sold under the trade name LAPONITE*, are products of Laporte Industries Inc. Laponites are synthetic hectorite clays composed of magnesium, lithium, silica, oxygen, hydrogen, and sodium-
  • Laponites are composed in the dry state of platelets arranged in stacks. Each platelet has a double layer of tetrahedral silica bonded to oxygen atoms. Between the two silica layers there is a sheet of cations composed of magnesium and lithium in a 5.3 to 0.7 ratio. These cations coordinate the inner row of silica bound oxygens and OH groups.
  • the partial substitution of Magnesium (+2) with Lithium (+ 1) imparts an overall negative charge to the silica surface.
  • compositions in which Laponite clays are dispersed so as to prevent or hinder the formation of gel structure demonstrate superior performance in desensitizing capability, as measured by tubule blocking experiments. Such compositions typically use higher amounts of clay than found with compositions manifesting ideal gel structures.
  • inorganic dispersants and organic polymeric dispersants enhance the desensitizing performance of the Laponite clay. Laponite clay-containing compositions with such added dispersants have superior efficacy, demonstrate pleasant organoleptic characteristics, and ar? compatible with fluoride and most other dentifrice ingredients.
  • Fluoride treated Laponite clays are preferred for their ability to coexist with fluoride in a dentifrice.
  • Dentifrices and mixtures containing fluoride sources and hectorite clays or fluoride treated Laponite clays were examined for fluoride bioava ⁇ ability, and dentifrices containing untreated hectorite clays reduced sodium fluoride availability, while fluoride treated Laponite clay dentifrices retained full fluoride bioavailability.
  • the dentifrice formulation is in the form of a paste or a gel that comprises from about 0.1% by weight to about 25% by wright of clay.
  • the clay comprises from about 1% clay to about 20% by weight of the clay, and, most preferably from about 2 % to about 15 %.
  • the clay may also be incorporated into other oral care formulations such as mouth rinses, as well as dentifrice formulations.
  • the flow reducing efficacy of the clay can surprisingly be improved by adding dispersants such as salts, thickeners, or other additives.
  • Preferred salts include: potassium salts, strontium salts (espedally preferred salts include desensitizing salts, such as potassium nitrate, potassium chloride, potassium bicarbonate and strontium chloride), and pyrophosphate salts, especially potassium and sodium tetrapyrophosphate salts and potassium and sodium add pyrophosphate salts.
  • Preferred thickeners include polymeric thickeners, and espedally preferred are cellulosic thickeners, including ionicaily modified cellulosic polymers such as sodium carboxymethyl cellulose, a product of Aqualon, and a cationically modified cellulosic polymer known as CELQUAT*, a product of National Starch and Chemical Company.
  • CELQUAT* a cationically modified cellulosic polymer known as CELQUAT*
  • hectorite clays espedally Laponite clays
  • the cationically charged modified cellulose and other positively charged entities can interact with the anionic face of the clay, re_rjlting in better dispersion of the clay leading to a particle size appropriate for penetrating dentin tubules, and a modification of the electrochemical characteristics of the particle resulting in enhanced electrostatic adherence of the clay to the tubule walL
  • aspects of clay chemistry are discussed in more detail in the Mayes article mentioned above and in U.S. Patent
  • Oral rinses using the clay can be in the form of oral solutions or dispersions.
  • Oral rinses may contain conventional flavors, colorants and other additives having organoleptic or therapeutic efficacy.
  • Dentifrices made using the hectorite clay will usually be water-based and will contain a humectant such as glycerin, sorbitol or other sugar alcohol, propylene glycol or polyethylene glycol.
  • the dentifrice may be a paste or a gel.
  • the gelling agent may be an alkali metal carboxymethyl cellulose, hydroxy ethyl cellulose or hydroxy methyl cellulose, xanlhan gum, viscarin, iota carrageenan, gelatin, starch, glucose, sucrose, polyvinyl pyrollidone, polyvinyl alcohol, gum tragacanth, gum daraya, hydroxy propyl cellulose, methyl cellulose and sodium alginate, and magnesium aluminum silicate gel.
  • polishing agents such as precipitated silica, hydrated silica and other known abrasive polishing agents, fluoride, detergents, coloring or
  • whitening agents such as titanium dioxide, fragrances and flavorings.
  • Additional therapeutic agents such as tartar control agents, i ⁇ art-ri?” agents such as Triclosan or chlorhexadine, may also be added.
  • a dentifrice in accordance with the invention may be made by mixing the ingredients in any conventional manner, for example by creating a gel with the water and gelling agent and then adding the water soluble ingredients. Finally, a surfactant is added and the hydrophobic ingredients are then added. The mixture is then packaged in a convention dentifrice container such as a tube, and applied to the surface of the teeth through conventional brushing, coating, painting or other direct or indirect application technique.
  • a convention dentifrice container such as a tube
  • This spedal leak proof chamber is connected to a pressurized fluid reservoir containing a tissue culture fluid.
  • a pressurized fluid reservoir containing a tissue culture fluid.
  • the fluid can be maintained at physiological pH.
  • the disks are wetted with human saliva to approximate the intraoral condition.
  • the apparatus includes a glass capillary tube mounted on a ruler or other measuring instrument. An air bubble is injected into the glass capillary tube. By measuring the displacement of this bubble as a function of time the fluid flow through the dentin disk can be measured. (It has been reported that fluid actually flows out of dentin tubules from the interior of a normal human tooth.)
  • the experimental mixture or dentifrice is applied to the external disk surface with a nylon brush. After a defined period of brushing, the experimental material is rinsed of ⁇ and the post application hydraulic conductance is measured. In this fashion the ability of various experimental materials, both alone and as components of dentifrice systems, can be tested for the ability to obstruct fluid flow in the dentinai tubules.
  • Combinations of Laponite clays with water and other specified ingredients were prepared and tested for flow reduction using the method set forth above. Each combination had the composition set out in Table 1 and had the flow reduction shown in Table 1.
  • the examples show the good dentin fluid flow reducing ability of hectorite clays, espedally when the clay is associated with a dispersant, such as a polymeric dispersant or salts.
  • a suitable mixer equipped with a vacuum system, such as whipmixer for the laboratory scale or

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cosmetics (AREA)
  • Fodder In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)

Abstract

La présente invention décrit un procédé de traitement des dents hypersensibles, au moyen d'une composition administrée par voie orale comprenant de l'hectorite, tout particulièrement de la laponite.
EP96910786A 1995-04-11 1996-04-10 Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents Expired - Lifetime EP0820270B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/419,816 US5589159A (en) 1995-04-11 1995-04-11 Dispersible particulate system for desensitizing teeth
US419816 1995-04-11
PCT/US1996/004852 WO1996032090A1 (fr) 1995-04-11 1996-04-10 Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents

Publications (3)

Publication Number Publication Date
EP0820270A1 true EP0820270A1 (fr) 1998-01-28
EP0820270A4 EP0820270A4 (fr) 1999-06-23
EP0820270B1 EP0820270B1 (fr) 2003-06-11

Family

ID=23663881

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96910786A Expired - Lifetime EP0820270B1 (fr) 1995-04-11 1996-04-10 Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents

Country Status (24)

Country Link
US (1) US5589159A (fr)
EP (1) EP0820270B1 (fr)
JP (1) JPH11509518A (fr)
KR (1) KR19980703780A (fr)
CN (1) CN1102379C (fr)
AR (1) AR004171A1 (fr)
AT (1) ATE242624T1 (fr)
AU (1) AU717149B2 (fr)
BG (1) BG101949A (fr)
BR (1) BR9604959A (fr)
CA (1) CA2217861A1 (fr)
CZ (1) CZ288829B6 (fr)
DE (1) DE69628643T2 (fr)
DK (1) DK0820270T3 (fr)
ES (1) ES2201180T3 (fr)
HK (1) HK1004108A1 (fr)
HU (1) HUP9801702A3 (fr)
NZ (1) NZ305772A (fr)
PL (1) PL184327B1 (fr)
PT (1) PT820270E (fr)
RU (1) RU2163798C2 (fr)
SK (1) SK137697A3 (fr)
UA (1) UA48965C2 (fr)
WO (1) WO1996032090A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885551A (en) * 1997-08-01 1999-03-23 Smetana; Alfred J. Treatment for dentinal hypersensitivity
US6241972B1 (en) * 1999-02-19 2001-06-05 Block Drug Company, Inc. Oral care formulation for the treatment of sensitivity teeth
NZ514069A (en) * 1999-03-12 2004-01-30 Pfizer Prod Inc Compositions comprising a potassium salt active ingredient including oral compositions for reducing dental nerve and dentin sensitivity comprising a non-menthol flavouring
EP1731132B1 (fr) 2000-10-13 2008-12-10 Block Drug Company, Inc. Compositions dentaires pour dents hypersensibles
US6447756B1 (en) * 2000-11-08 2002-09-10 Colgate Palmolive Company Desensitizing dual component dentifrice
US6416745B1 (en) 2001-05-03 2002-07-09 Block Drug Company, Inc. Dental composition for treating hypersensitive teeth
AU2005270010A1 (en) * 2004-07-02 2006-02-09 Discus Dental, Llc. Dental compositions with sensitivity relief
EP1868689B1 (fr) 2005-03-21 2015-05-27 Glaxo Group Limited Formule de dentifrice sans sulfate d'alkyle ni orthophosphate comprenant une source de fluorure et un abrasif dentaire à base de silice
US20070140992A1 (en) * 2005-12-21 2007-06-21 Lynn Schick Taste masking of essential oils using a hydrocolloid
US20080268001A1 (en) * 2007-04-30 2008-10-30 Lynette Zaidel Oral care composition to reduce or eliminate dental sensitivity
PL2249784T3 (pl) 2008-02-08 2016-12-30 Produkt do higieny jamy ustnej i sposoby jego stosowania i wytwarzania
US20100047742A1 (en) * 2008-08-25 2010-02-25 Pitcock Jr William Henry Tubule-blocking silica materials for dentifrices
TWI469795B (zh) 2009-04-01 2015-01-21 Colgate Palmolive Co 防止過敏和促進再礦化之雙作用牙劑組成物
US20110206749A1 (en) * 2010-02-19 2011-08-25 J.M. Huber Corporation Silica materials for reducing oral malador
US8658139B1 (en) 2010-02-27 2014-02-25 Squigle, Inc. Prevention and treatment of oral diseases
US20110236444A1 (en) * 2010-03-25 2011-09-29 Darsillo Michael S Antimicrobial Silica Composites
ES2529216T3 (es) 2010-06-23 2015-02-18 Colgate-Palmolive Company Composición oral terapéutica
EP2637634B1 (fr) 2010-11-12 2017-05-17 Colgate-Palmolive Company Produit d'hygiène orale, procede d'utilisation et de fabrication de celui-ci
CN107432832A (zh) 2010-11-12 2017-12-05 高露洁-棕榄公司 口腔护理产品及其使用和制备方法
SG190023A1 (en) * 2010-12-07 2013-06-28 Colgate Palmolive Co Dentifrice compositions containing calcium silicate
US9717929B2 (en) * 2010-12-07 2017-08-01 Colgate-Palmolive Company Dentifrice compositions containing calcium silicate and a basic amino acid
JP5720416B2 (ja) * 2011-05-19 2015-05-20 ライオン株式会社 ゲル状口腔用組成物及びその製造方法
AU2011383635B2 (en) * 2011-12-21 2014-10-23 Colgate-Palmolive Company Oral care compositions
AU2013408427B2 (en) * 2013-12-16 2017-02-02 Colgate-Palmolive Company Oral care compositions comprising calcium carbonate and a clay
BR112016013067A2 (pt) * 2013-12-16 2018-05-22 Colgate Palmolive Co composições de cuidado oral compreendendo carbonato de cálcio e talco
WO2021078685A1 (fr) 2019-10-23 2021-04-29 Unilever Ip Holdings B.V. Procédé de réduction de l'hypersensibilité dentaire
EP4021585A1 (fr) 2020-03-27 2022-07-06 Colgate-Palmolive Company Compositions de soin bucco-dentaire et procédés d'utilisation
EP4021386A1 (fr) 2020-03-27 2022-07-06 Colgate-Palmolive Company Compositions de soins bucco-dentaires et procédés d'utilisation
MX2024003347A (es) 2021-09-23 2024-04-08 Colgate Palmolive Co Composiciones para el cuidado oral y metodos de uso.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418053A (en) * 1980-03-17 1983-11-29 Indiana University Foundation Dental prophylaxis compositions and their use
JPH0742219B2 (ja) * 1984-07-26 1995-05-10 ライオン株式会社 口腔用組成物
US4992258A (en) * 1989-10-23 1991-02-12 Colgate-Palmolive Company Dentrifice composition
AU8733491A (en) * 1990-10-25 1992-05-26 Boots Company Plc, The Mouthwash
GB9115153D0 (en) * 1991-07-12 1991-08-28 Patel Bipin C M Sol-gel composition for producing glassy coatings
GB9115154D0 (en) * 1991-07-12 1991-08-28 Patel Bipin C M Sol-gel composition for producing glassy coatings
US5250288A (en) * 1991-09-13 1993-10-05 Gillette Canada, Inc. Method for desensitizing teeth
US5211939A (en) * 1991-09-13 1993-05-18 Gillette Canada Method for desensitizing teeth
US5374417A (en) * 1991-10-17 1994-12-20 Colgate Palmolive Company Desensitizing dentifrice
US5240697A (en) * 1991-10-17 1993-08-31 Colgate-Palmolive Company Desensitizing anti-tartar dentifrice
US5270031A (en) * 1991-12-20 1993-12-14 Block Drug Company Inc. Dentinal desensitizing compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9632090A1 *

Also Published As

Publication number Publication date
NZ305772A (en) 1999-02-25
CZ288829B6 (cs) 2001-09-12
EP0820270B1 (fr) 2003-06-11
DE69628643D1 (de) 2003-07-17
ES2201180T3 (es) 2004-03-16
BR9604959A (pt) 1998-07-14
BG101949A (en) 1998-05-29
PL322719A1 (en) 1998-02-16
KR19980703780A (ko) 1998-12-05
AU717149B2 (en) 2000-03-16
DK0820270T3 (da) 2003-09-29
AU5388596A (en) 1996-10-30
CA2217861A1 (fr) 1996-10-17
HK1004108A1 (en) 1998-11-20
HUP9801702A2 (hu) 1998-11-30
DE69628643T2 (de) 2004-04-29
SK137697A3 (en) 1998-05-06
PL184327B1 (pl) 2002-10-31
HUP9801702A3 (en) 1998-12-28
RU2163798C2 (ru) 2001-03-10
CN1102379C (zh) 2003-03-05
WO1996032090A1 (fr) 1996-10-17
JPH11509518A (ja) 1999-08-24
CZ321097A3 (cs) 1998-03-18
US5589159A (en) 1996-12-31
PT820270E (pt) 2003-10-31
ATE242624T1 (de) 2003-06-15
UA48965C2 (uk) 2002-09-16
CN1186426A (zh) 1998-07-01
AR004171A1 (es) 1998-11-04
EP0820270A4 (fr) 1999-06-23

Similar Documents

Publication Publication Date Title
EP0820270B1 (fr) Systeme particulaire pouvant etre mis en dispersion pour desensibiliser les dents
EP1202705B1 (fr) Composition destinee a traiter la hypersensitivite de la dentine
EP1390004B1 (fr) Composition de soins dentaires pour traiter des dents hypersensibles
EP0760647B1 (fr) Soulagement de l'hypersensibilite dentinaire au moyen de particules submicroniques
JPH1017445A (ja) 口腔用組成物及びその製造方法
CA2420154A1 (fr) Composition dentaire pour dents hypersensibles
US20070059257A1 (en) Dentinal composition for hypersensitive teeth
EP2882499B1 (fr) Procédés et compositions pour traiter l'hypersensibilité dentaire
US5885551A (en) Treatment for dentinal hypersensitivity
NZ204974A (en) Thickened aqueous sodium fluoride compositions for dental care
EP2882500A1 (fr) Procédés et compositions de traitement d'hypersensibilité dentaire
MXPA97007819A (en) System in dispersible particles to insensibilize dien
US8951506B2 (en) Formulation and method for treatment of teeth
JP2002068948A (ja) 口腔用組成物及び咀嚼組成物
JP2000095655A (ja) 口腔組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990507

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020307

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030611

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69628643

Country of ref document: DE

Date of ref document: 20030717

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030911

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

Ref country code: CH

Ref legal event code: NV

Representative=s name: ING. MARCO ZARDI C/O M. ZARDI & CO. S.A.

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2201180

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040410

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040430

26N No opposition filed

Effective date: 20040312

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: ISLER & PEDRAZZINI AG;POSTFACH 1772;8027 ZUERICH (CH)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20080319

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080414

Year of fee payment: 13

Ref country code: CH

Payment date: 20080425

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080318

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20080507

Year of fee payment: 13

Ref country code: PT

Payment date: 20080410

Year of fee payment: 13

Ref country code: IT

Payment date: 20080416

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080404

Year of fee payment: 13

Ref country code: IE

Payment date: 20080424

Year of fee payment: 13

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20091012

BERE Be: lapsed

Owner name: *BLOCK DRUG CY INC.

Effective date: 20090430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090430

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090430

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091012

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090410

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090430

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090411

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120327

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20120425

Year of fee payment: 17

Ref country code: DE

Payment date: 20120430

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120503

Year of fee payment: 17

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69628643

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20131101

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131101

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130410

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20131231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131101

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 69628643

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0007160000

Ipc: A61K0008260000

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69628643

Country of ref document: DE

Effective date: 20131101

Ref country code: DE

Ref legal event code: R079

Ref document number: 69628643

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0007160000

Ipc: A61K0008260000

Effective date: 20140526